ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2026
Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany.BMC nephrology · 2026Article
- Living Donor Kidney Transplantation in High-Recurrence Kidney Diseases: Precision Risk Stratification and Management.Kidney international reports · 2026Review
- Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAtypical haemolytic uraemic syndrome (aHUS) is a rare but severe condition caused by complement dysregulation. Eculizumab prophylaxis prevents recurrence and improves survival, yet the benefits of lifelong treatment for patients are uncertain and the long-term costs for health services are substantial. This economic evaluation applied the results from the Stopping Eculizumab Treatment Safely in aHUS (SETS aHUS) trial and assessed the cost-effectiveness of replacing lifelong eculizumab with a disease monitoring strategy over the long term.
methodsA Markov model was used to estimate cost and quality-adjusted life years (QALYs) for a treatment withdrawal and disease monitoring strategy over the long term. Results from the SETS aHUS trial informed the risk of relapse diagnosis or progression, utility values and additional healthcare use. Time to relapse diagnosis was extrapolated using parametric survival functions.
resultsThe treatment withdrawal and disease monitoring strategy increased average patient QALYs by 0.08 [95% credible interval (CrI) -0.33-0.53], and reduced patient costs by £4 234 196 (95% CrI -£684 495 to -£6 403 694) compared with the lifelong delivery of eculizumab. The impact on survival estimates was low, as withdrawal patients had an average reduction of 0.0005 patient life years (LYs) (95% CrI -0.0029-0) over an 80-year time horizon. Withdrawal and monitoring had a 64% likelihood of being more effective and less costly than lifelong treatment. Results remained robust across multiple scenarios exploring uncertainties.
conclusionTreatment withdrawal and disease monitoring was cost-effective compared with lifelong eculizumab therapy. Its adoption is expected to substantially reduce costs per patient and may improve average patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.